https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.tw
Main Products/ Services/ Pipelines & Platforms
ASD141 ▪ First-in-the-class innate immune checkpoint inhibitor ▪ Break the bottleneck of cancer immunotherapy through preventing a novel regulatory ligand to induce innate cold in TME ▪ Significantly enrich the infiltration of functional APCs and neoantigen specific CD8 in TME ▪ Very synergetic with effector cell level of ICIs (antiPD1/PDL1/CTLA4) ▪ Dramatically ameliorate the acute injection reactions when combined with antiCTLA4 ▪ Excellent tolerability in pharmacology and PK studies ▪ Under preclinical development and plan to submit IND soon NanoCherub ▪ A versatile ElectroKinetic nanocomplex antigen adjuvant/delivery platform for vaccine development ASD253 ▪ Therapeutic vaccine for HBV achieved 100% functional cure pharmacologically ( HDI /AAV models) ▪ No LFT abnormality in both animal models ▪ Under preclinical development ASD254 ▪ RBD/RBM based subunit protein vaccine of Covid-19 ▪ Nonpolarized Th1/Th2 immunogenicity ▪ Long lasting protection and maintain good protection to VOCs ▪ Under preclinical development
Business Interests
We are seeking out-licensing opportunities and co-developing our assets or R&D collaboration: ▪ ASD141, first in the class innate immune checkpoint inhibitor ▪ ASD253, therapeutic vaccine for hepatitis B ▪ ASD254, RBD based subunit protein, preventive vaccine of Covid-19 We are also interested in engaging potential investors.
Contact Info
Teresa Chou
VP
+886-2-7728-8922
contact@ascendobiotech.com